Latest Breaking News On - ஜெஃப்ரி ஹாட்ஃபீல்ட் - Page 2 : vimarsana.com

MedCity News Biotech Vividion lands $135M in crossover cash, paving a path to the public markets Vividion Therapeutics has technology that enables it to develop drugs for “undruggable” disease targets. The Series C financing is a crossover round, an indication a biotech is preparing for an IPO. Shares0   Vividion Therapeutics has technology that finds ways to hit promising disease targets that were previously deemed “undruggable.” Now it has $135 million that might allow it to find something else: a public stock listing. The Series C round of financing announced Wednesday included so-called crossover investors, firms that invest in both public and private companies. Securing crossover investment is one of the steps companies take as they prepare for an IPO.

Benjamin cravattAaron davisJeffrey hatfieldScripps research instituteBoxer capital of tavistock groupBristol myers squibbT rowe price associatesSan diego basedScripps researchLogos capitalBoxer capitalSoftbank investment advisersAvoro capital advisorsPrice associatesSurveyor capitalWoodline partners